Subject of the day
MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $60.12B | +5.9% | |
| Net income | $18.25B | +2.2% | |
| Cash from ops | $16.47B | +12.9% |
$135.55
▲ +2.63 (+2.0%)
| 52w hi | $135.55 |
|---|---|
| 52w lo | $75.83 |
| Vol | 6.91M |
| As of | Aug 13 |
Our score +0.28
| Short | +0.21 |
|---|---|
| Medium | +0.40 |
| Long | +0.16 |
computed 2026-08-13
Merck & Co., Inc.
Healthcare · Drug Manufacturers - General
| Market cap | $334.43B |
|---|---|
| Enterprise value | $374.76B |
| Trailing P/E | 108.44x |
| Forward P/E | 14.20x |
| EV / EBITDA | 12.98x |
| P / S (ttm) | 5.02x |
| Profit margin | 4.8% |
| Return on equity | 7.0% |
| Revenue growth | +5.1% |
| Earnings growth | — |
| Debt / equity | 128.41 |
| Beta vs SPX | 0.28 |
|---|---|
| Corr SPX | 0.17 |
| Annual vol | 27.3% |
| Annual ret | +12.4% |
| Sharpe | 0.45 |
| Max DD | -38.1% |
Window: 504 trading days (504 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.14 | |
| Sector | +0.12 | |
| Technical | +0.18 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $133.86 | $135.68 | $133.05 | $135.55 | 6.91M |
| Aug 12 | $130.25 | $134.06 | $128.91 | $132.92 | 10.45M |
| Aug 11 | $129.93 | $132.84 | $129.70 | $130.42 | 6.34M |
| Aug 10 | $128.29 | $130.98 | $128.24 | $130.92 | 6.01M |
| Aug 7 | $127.84 | $128.75 | $126.68 | $128.58 | 7.35M |